InMed Pharmaceuticals (INM) has released an update to notify the public and investors about a regulation fd disclosure.
The Company has announced the appointment of Ms. Jagpal as the new Chief Financial Officer and Corporate Secretary, a strategic move signaling potential shifts in the company’s financial strategy. This key update, intended for current and prospective investors, highlights the company’s ongoing commitment to leadership and governance, without bearing any legal weight as a formally filed document under securities regulations.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
